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Aims Clinical observations in patients with long QT syndrome carrying sodium channel mutations (LQT3) suggest that bra-
dycardia caused by parasympathetic stimulation may provoke torsades de pointes (TdP). b-Adrenoceptor blockers
appear less effective in LQT3 than in other forms of the disease.
Methods
and results
We studied effects of autonomic modulation on arrhythmias in vivo and in vitro and quantiﬁed sympathetic innervation
by autoradiography in heterozygous mice with a knock-in deletion (DKPQ) in the Scn5a gene coding for the cardiac
sodium channel and increased late sodium current (LQT3 mice). Cholinergic stimulation by carbachol provoked bige-
mini and TdP in freely roaming LQT3 mice. No arrhythmias were provoked by physical stress, mental stress, isopro-
terenol, or atropine. In isolated, beating hearts, carbachol did not prolong action potentials per se, but caused
bradycardia and rate-dependent action potential prolongation. The muscarinic inhibitor AFDX116 prevented
effects of carbachol on heart rate and arrhythmias. b-Adrenoceptor stimulation suppressed arrhythmias, shortened
rate-corrected action potential duration, increased rate, and minimized difference in late sodium current between
genotypes. b-Adrenoceptor density was reduced in LQT3 hearts. Acute b-adrenoceptor blockade by esmolol, pro-
pranolol or chronic propranolol in vivo did not suppress arrhythmias. Chronic ﬂecainide pre-treatment prevented
arrhythmias (all P , 0.05).
Conclusion CholinergicstimulationprovokesarrhythmiasinthismodelofLQT3bytriggeringbradycardia.b-Adrenoceptordensity
is reduced, and b-adrenoceptor blockade does not prevent arrhythmias. Sodium channel blockade and b-adrenoceptor
stimulation suppress arrhythmias by shortening repolarization and minimizing difference in late sodium current.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Gain-of-function mutations in the cardiac sodium channel gene Scn5a
can cause long QT syndrome 3 (LQT3) and arrhythmic death by
torsades de pointes (TdP).
1 In contrast to most patients carrying
mutations in potassium channel genes,
2 TdP and death occur predo-
minantly during bradycardia, intermittent AV block, or sleep in LQT3
patients.
2–8 While these observations may suggest that heightened
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systematically studied.
b-Adrenoceptor-blockers, the standard ﬁrst-line therapy in long
QT syndrome patients, seem to be less efﬁcacious in LQT3 in clinical
observations.
9 Sodium channel blockers are increasingly used as part
of antiarrhythmic therapy in LQT3, mainly based on acute effects of
such drugs in isolated cells and organs,
10–12 and on a QT-shortening
effect in LQT3 patients.
13 The interaction between chronic sodium
channel inhibition and autonomic triggers for arrhythmias in LQT3
has not yet been studied.
We therefore systematically studied effects of acute and chronic
autonomic modulation in vivo and in vitro in heterozygous DKPQ-Scn5a
knock-in mice with LQT3 (DKPQ-SCN5A).
14,15
2. Methods
The investigation conforms with the Guide for the Care and Use of Labora-
tory Animals published by the US National Institutes of Health (NIH Pub-
lication No. 85-23, revised 1996) and was approved by the local
institutional review board (G61/99, G83/2004). Combination of chronic
and acute pharmacologic interventions during telemetry is illustrated in
Figure 1. Additional experiments were performed in isolated, beating
hearts and isolated myocytes. Experiments and analyses performed in
adult littermate wild-type and heterozygous DKPQ-SCN5A mice aged
22+9 weeks (mean+SD) were blinded to genotype and type of
therapy. Genotyping was performed as described by Nuyens et al.
16 and
in supplemental methods. Chemicals used were from Sigma-Aldrich,
Munich, Germany, if not indicated otherwise.
2.1 Arrhythmias in freely roaming mice and
during in vivo interventions
We implanted telemetric ECG transmitters (DSI, St Paul, MN, USA) and
recorded telemetric ECGs during normal activity for 24 h, standardized
swimming exercise, and repetitive warm air jet challenges
17 at baseline,
after 5 days of chronic b1-b2-adrenoceptor-blocker propranolol
(propranololhydrochloride) 3.5 mg/day per os (p.o.) resulting in rate
reduction and therapeutic plasma levels (77.5+6.5 ng/mL)
18 or after 10
days of sodium channel blocker ﬂecainide treatment (50 mg/5 mL, MEDA
Pharma,BadHomburg,Germany),45 mg/kg/dayp.o.,resultingintherapeutic
plasma levels (509+110 ng/mL), both applied orally via drinking water,
mean ﬂuid intake 7.1+0.3 mL SD, or 0.2 mL/kg body weight (BW)/day
(Figure 1). The cholinergic agonist carbachol [carbamylcholine chloride,
0.5 mg/kg intraperitoneally (i.p.)], the anticholinergic drug atropine (0.5 mg/
kg i.p.), the antimuscarinic agent AFDX116 (Tocris, Ellisville, MO, USA) at
5,12.5,25,50 mg/kgBWi.p.,andthe b-adrenergiccatecholamineisoproter-
enol (isoproterenol hydrochloride 2 mg/kg i.p.) were applied separately.
Heart rate variability was calculated as the standard deviation
of RR-intervals during periods of rest and exercise of at least
5m i n .
19,20
2.2 Electrophysiological study in isolated,
beating hearts
A tissue bath ECG, and right and left ventricular monophasic action
potentials (MAP) were simultaneously recorded from isolated, beating
Langendorff-perfused hearts with mechanically induced AV block during
spontaneous rhythm and pacing
15,21 at baseline, after adding b1-b2-
adrenoceptor-stimulator orciprenaline (1.7   10
26 M) with and without
b1-b2-adrenoceptor-blocker esmolol 10
27–10
25 M (100 mg /10 mL,
Baxter, Munich, Germany), or propranolol 1.7   10
26 M and 1.7  
10
27 M applied in random order. Carbachol 10
27–10
25 M was applied
in hearts without AV block.
2.3 Microautoradiography for cardiac
b-adrenoceptors
After perfusion with modiﬁed Krebs–Henseleit solution,
15,21 hearts were
embedded in Tissue-Tek
w (Sekura, Heppenheim, Germany) and frozen.
Cryoﬁxated hearts were sliced in short axis orientation (20 mm). For
each heart, a pair of adjacent tissue sections was prepared. Microautora-
diography was performed as described.
22 Tissues were incubated in a
buffer solution [50 nM HEPES, 5 mM MgCl2, 3% BSA, ph 7.4 (Roth, Karls-
ruhe, Germany)] for 10 min and dried. Tissues were then coated with sol-
utions of radioactively labelled b-adrenoceptor antagonist
125I-ICYP
(Perkin Elmer, Rodgau-Ju ¨gesheim, Germany). A uniform radioligand con-
centration of 80 pM (approximately ﬁve times dissociation constant)
was chosen to ensure a plateau in speciﬁc binding after 2 h of incu-
bation.
22,23 Tissues were washed in PBS (Invitrogen, Karlsruhe,
Germany) and distilled water afterwards. To differentiate speciﬁc from
unspeciﬁc binding, one of two slices was additionally incubated with an
excess of unlabelled L-propranolol (10 mM). Microautoradiography was
performed for 8 h using a high-resolution digital autoradiography system
(Micro Imager, Biospace Lab, France). Short axis sections were analysed
by manual segmentation of left ventricle using ImageJ (Rasband, National
Institutes of Health, Bethesda, USA). Speciﬁc binding representing
b-adrenoceptor density was calculated by subtraction of unspeciﬁc
binding (
125I-ICYP þ Propranolol) from total tracer binding (
125I-ICYP).
2.4 Whole-cell voltage clamp experiments in
isolated ventricular cardiomyocytes
Peak and late sodium current was recorded at room temperature (228C)
at baseline and during b-adrenoceptor-stimulation with isoproterenol
from rod-shaped, striated, and Ca
2þ-tolerant cells within 8 h of isolation
using standard solutions and techniques.
12,14,24 Currents were recorded
with an HEKA-EPC 9 ampliﬁer, and data were collected and analysed
with PULSE (HEKA Elektronik, Lambrecht/Pfalz, Germany), Kaleidagraph
4.0 (Synergy, Reading, PA), and IGOR (WaveMetrics, Lake Oswego,
OR) software. Isoproterenol (1.6 mM) diluted in external solution was
applied with a motorstepper-controlled perfusion system. The holding
Figure 1 In vivo study ﬂow chart. Telemetry at baseline and during
chronic pharmacological interventions (columns), baseline and acute in
vivo stress tests and pharmacological modulation of the autonomic
nervous system (rows). Additional experiments were performed ex
vivo(functionalstudies,cellularelectrophysiology,andautoradiography).
Autonomic modulation and therapy in LQT3 61potential was 2100 mV, test pulse to 0 mV. Whole cell currents were
recorded without pharmacological testing.
2.5 Statistical analyses
Paired and unpaired t-tests, univariate analysis of variance (ANOVA), and
ANOVA analyses for multiple comparisons and repetitive measurements
were used to compare continuous parameters (SPSS, version 12.0G for
Windows). Fisher’s exact test was used to compare arrhythmia occur-
rence. Values are reported as mean+SEM unless indicated otherwise.
Differences were considered signiﬁcant at a two-tailed alpha level of
P , 0.05 and marked by an asterisk (*) unless indicated otherwise.
3. Results
3.1 DKPQ-SCN5A mice show bradycardia
and TdP-like arrhythmias during sleep
DKPQ-SCN5A mice had more spontaneous pauses than WT litter-
mate due to asystole or intermittent AV block during sleep
(Figure 2A). 3/21 DKPQ-SCN5A mice died spontaneously during long-
term telemetric ECG monitoring showing extreme bradycardia (3/3)
and TdP-like polymorphic ventricular arrhythmias (1/3) prior to death
(Figure 2B). None of 17 WT died spontaneously during monitoring.
Heart rate was lower in freely roaming DKPQ-SCN5A mice com-
pared with WT at rest and during stress (Table 1, Figure 2C).
3.2 Stress in freely roaming DKPQ-SCN5A
mice does not provoke arrhythmias
Mental stress, exercise, b-adrenoceptor-stimulation (isoproterenol
2 mg/kg i.p.), or parasympathetic block by atropine (0.5 mg/kg i.p.)
increased heart rate irrespective of genotype in freely roaming mice
(Table 1). We never observed arrhythmias under these conditions.
At high heart rate, QT intervals did not differ between genotypes,
indicating alleviation of the long QT phenotype in vivo (Table 2).
DKPQ-SCN5A mice showed relative bradycardia compared with
WT during physiological stress tests (Table 1).
3.3 Cholinergic stimulation in vivo provokes
arrhythmias in DKPQ-SCN5A
Cholinergic stimulation with carbachol, a clinically used non-speciﬁc
muscarinic and nicotinic agonist, aggravated bradycardia [0.5 mg/kg
i.p. (approximately 0.275 mmol/kg), Table 1, Figures 2E, 3A and D], pro-
longed QT interval (Table 2, Figure 3C), and provoked bigemini or runs
of TdP in DKPQ-SCN5A mice (Figures 2E and 3). WT mice showed
similar bradycardia after carbachol challenge, but only sporadic ventri-
cular extrasystoles and neither bigemini nor TdP (Figure 3, Table 1).
Atropine (0.5 mg/kg i.p.) prevented carbachol-induced bradycardia
and related arrhythmias (n ¼ 3/3 DKPQ-SCN5A mice). The muscar-
inic receptor blocker AFDX116, 12.5, 25, or 50 mmol/kg BW,
applied 15 min before carbachol, abolished the effect of carbachol
and prevented arrhythmias in n ¼ 3/3 DKPQ-SCN5A mice
(Figure 3D, see Supplementary material online, Figure S2).
3.4 Chronic b-adrenoceptor-blockade does
not prevent carbachol-induced arrhythmias
in vivo
Chronic propranolol therapy reduced heart rate, heart rate variability,
and heart rate increase during 24 h monitoring, swimming, and mental
stress in freely roaming WT and DKPQ-SCN5A mice (Figure 2D,
Table 1). Chronic propranolol therapy (3.5 mg/day) did not prevent
carbachol-provoked arrhythmias (8/12 TdP or bigemini in
DKPQ-SCN5A with propranolol *vs. 0/9 WT, Figure 3, Table 1).
However, care had to be taken to keep animals in a stressless environ-
ment during cholinergic stimulation because physical or mental acti-
vation of animals resulted in cessation of arrhythmias.
3.5 Carbachol provokes bigemini and TdP
in isolated DKPQ-SCN5A hearts
Carbachol perfusion caused similar effects on the isolated heart as
in vivo, i.e. bradycardia, bigemini, and TdP: Cycle length was
739 + 171 ms during carbachol 10
27 M; 1128+310 ms during car-
bachol 10
26 M( * v s .2 3 4 +17 ms baseline). Bigemini occurred in
33/42 and TdP in 13/42 DKPQ-SCN5A hearts during carbachol
(*vs. 22/42 bigemini and 4/42 TdP at baseline, Figure 4A). Carbachol
neither induced arrhythmias nor prolonged APD during controlled
rates (Supplementary material online, Table), but increased spon-
taneous APD by decreasing heart rate in DKPQ-SCN5A hearts
(APD90: baseline 45+2 ms, carbachol 10
27 M6 4 +7m s ,
carbachol 10
26 M8 7 +7 ms, *vs. baseline and *vs. WT, Figure 4B
and C).
3.6 b-Adrenoceptor-blockade impairs
antiarrhythmic effects of catecholamines
and can prolong ventricular action
potentials in isolated hearts from
DKPQ-SCN5A mice
b-Adrenoceptor-stimulation by orciprenaline (1.7 mM) completely
prevented and suppressed EADs and TdP in isolated hearts with
mechanical AV block (0/16 DKPQ-SCN5A hearts *vs. baseline 4/13,
Figure 5A and B). Orciprenaline shortened ventricular APD
(Figure 6A and B) and decreased APD dispersion at paced cycle
lengths of 200 and 300 ms (orciprenaline 9+1 *vs. baseline 19+
2 ms). Propranolol (1.7   10
26 M and 1.7   10
27 M) did not
prolong APD in DKPQ-SCN5A hearts (data not shown). Co-infusion
of esmolol and orciprenaline rendered APD similar to baseline values
in WT (þ9% APD), but caused prolongation of APD and dispersion
of APD up to 25% above baseline values in DKPQ-SCN5A hearts
(P , 0.05, Figure 6B). Orciprenaline lost its antiarrhythmic effect in
the presence of propranolol or esmolol (Figure 5B). Propranolol
slowed intrinsic ventricular rhythm after AV block even in presence
of equimolar orciprenaline, and complete asystole was more frequent
(5/12 DKPQ-SCN5A hearts, *vs. baseline 1/27). Propranolol alone
(1.7   10
26 M) suppressed EADs and TdP in hearts with mechanical
AV block, but caused bradycardia with temporary loss of ventricular
rhythm in 4/4 DKPQ-SCN5A isolated hearts. Orciprenaline caused
accelerated regular ventricular rhythms in all isolated hearts.




L. Fabritz et al. 62Figure 2 Illustrations of intrinsic bradycardia and arrhythmias in DKPQ-SCN5A mice. (A) Telemetric ECG of pauses and atrioventricular block in
unrestrained DKPQ-SCN5A mice. (B) Bradycardia-induced lethal torsades de pointes storm in an unrestrained DKPQ-SCN5A mouse. Within 30 min,
21 torsades de pointes episodes (duration 10 s–min) occurred. (C) Heart rate in unrestrained DKPQ-SCN5A and littermate WT mice during 24 h
monitoring (mean+SEM). DKPQ-SCN5A were bradycardic. (D) Propranolol decreased heart rates and blunted changes between rest during the day
and activity at night and between genotypes. (E) Carbachol-induced episode of bradycardia with intermittent bigemini and torsades de pointes like
arrhythmias in a DKPQ-SCN5A mouse.
Autonomic modulation and therapy in LQT3 633.8 b-Adrenoceptor-stimulation blunts the
difference in INa, late between
DKPQ-SCN5A and WT cardiomyocytes
Late sodium current (INa, late) was increased in DKPQ-SCN5A cardi-
omyocytes (Figure 7). Peak (early) sodium current densities did not
differ between groups under both conditions (P ¼ ns, Figure 7).
Isoproterenol (10
26 M superfusion) increased INa, late in both geno-
types. INa, late was not different between genotypes during adrenergic
stimulation (*vs. baseline; P ¼ ns for DKPQ-SCN5A vs. WT) due to a
higher relative increase of INa, late in WT cells compared with
DKPQ-SCN5A (increase in INa, late in DKPQ-SCN5A 49+10%,
WT 90+24%, Figure 7).
................................................ .................................................
.......................................................................................................................................................................................
Table 2 ECG parameters in unrestrained DKPQ-SCN5A and WT mice
PQ duration (ms) QT interval (ms)
WT DKPQ-SCN5A WT DKPQ-SCN5A
Baseline 600 b.p.m. 32.5+0.7 32.6+0.6 48.9+0.9 53.1+0.7*
450 b.p.m. 34.7+0.6 35.8+0.6 55.6+1.4 62.5+1.3*
n 13(13) 23(23) 13(13) 23(23)
Propranolol 600 b.p.m. 29.7+1.0** 32.6+0.5* 50.0+2.0 54.8+1.0
450 b.p.m. 32.1+1.2 35.1+0.7* 55.6+1.2 63.0+1.7*
n 5(5) 11(11) 5(5) 11(11)
Carbachol i.p. mono 200 b.p.m. 33.4+0.9 38.3+0.9* 104.0+3.7** 129.7+4.2*
, **
n 14(10) 18(16) 14(10) 18(16)
Carbachol i.p. þpropranolol 200 b.p.m. 36.3+3.1 37.4+1.2 108.8+3.4** 121.7+4.9**
n 5(4) 7(5) 5(4) 7(5)
Carbachol i.p. þ ﬂecainide 200 b.p.m. 38.9+1.5** 44.2+2.7** 127.9+4.0** 133.8+3.9**
n 7(4) 7(4) 7(4) 7(4)
Isoproterenol i.p. 700 b.p.m. 29.9+0.5 31.5+0.7 51.9+0.8 51.9+2.3
n 9(7) 14(12) 9(7) 14(12)
Swim stress 700 b.p.m. 30.2+1.8 26.5+2.3 52.0+5 40.4+3.5
n 3(3) 5(5) 3(3) 5(5)
Air jet stress 700 b.p.m. 29.7+0.5 29.3+1.7 53.5+2.0 51.1+2.4
n 3(3) 5(5) 3(3) 5(5)
Stable frequencies of at least 3   20 beats for generation of summary ECG potentials were selected (200–700 b.p.m.); n given as episodes analysed (n animals in brackets); mean+SEM.
*P , 0.05 vs. WT.
**P,0.05 vs. baseline at 450 and 600 b.p.m.
....................................................... ...............................................................
.......................................................................................................................................................................................
Table 1 Heart rate, sinus pauses, and AV block in unrestrained mice at baseline and effect of acute and chronic interventions
Baseline Propranolol
WT DKPQ-SCN5A WT DKPQ-SCN5A
Mean heart rate (HR) 24 h 548+47(16) 498+52*(18) 489+33***(13) 474+40*
, ***(15)
HR variability SD-HR 76+15(16) 86+15(18) 57+13***(13) 64+14***(15)












HR isoproterenol i.p. 725+41**(11) 694+35*
, **(14) 699+71**(4) 710+26**(4)
HR atropine i.p. 641+42**(3) 612+68**(6) no value no value
HR carbachol i.p. 223+38**(7) 230+51**(9) 190+21**(4) 240+46**(4)
HR carbachol i.p. prior ES 207+40**(4) 210+54**(8) 180+24**(4) 207+43**(6)
AVB or pauses/5 min/24 h 1.4+1.3(6) 3.1+1.8*(6) 1.7+1.4(6) 2.5+1.4*(6)
Max pause (ms cycle length) 227(6) 601(6) 489(5) 993(6)
Mean+SD of heart rates (n of mice in brackets) in unrestrained DKPQ-SCN5A and littermate WT mice at baseline and during chronic oral propranolol treatment. Pauses or AV block
numbers were determined as mean of 24 5-min-time periods over 24 consecutive hours per animal.
b.p.m., beats per minute; HR, variability SD-HR standard deviation of heart rate; i.p., intraperitoneal (time 2–12 min after i.p. injection was analysed, only sinus beats counted); ES,
extrasystole (10 beats prior to ﬁrst ES or arrhythmia analysed); AVB, atrioventricular block.
*P , 0.05 DKPQ-SCN5A vs. WT.
**P , 0.05 heart rate vs. respective 24 h heart rate.
***P , 0.05 baseline vs. propranolol.
L. Fabritz et al. 64Figure 3 Effect of carbachol on ECG morphology and arrhythmias in unrestrained DKPQ-SCN5A mice with and without chronic propranolol or
ﬂecainide treatment. (A) Representative telemetry ECG recordings at baseline and during carbachol challenge with and without chronic propranolol or
ﬂecainide treatment in unrestrained DKPQ-SCN5A mice. (B) Bar graphs give numbers of experiments with arrhythmias (ﬁlled bars, one to three
challenges per animal) and without arrhythmias (open bars) in both genotypes. Carbachol induced arrhythmias in DKPQ-SCN5A mice only.
Chronic ﬂecainide prevented arrhythmias, chronic propranolol did not (all P , 0.05). (C) QT interval in unrestrained DKPQ-SCN5A and littermate
WT mice. Tele-electrocardiographic summary potentials selected from spontaneous frequencies during heart rates at baseline (600 b.p.m, 450 b.p.m.),
and low (200 b.p.m.) heart rates after carbachol challenge with or without chronic ﬂecainide therapy. Carbachol-induced bradycardia exacerbated QT
prolongation in DKPQ-SCN5A, (values and animal numbers in Table 2).
Autonomic modulation and therapy in LQT3 653.9 Chronic ﬂecainide therapy prevents
arrhythmias induced by cholinergic
stimulation in freely roaming
DKPQ-SCN5A mice
Chronic ﬂecainide (45 mg/kg BW/day) did not prevent
carbachol-induced bradycardia (WT 223+33 b.p.m., vs. DKPQ-
SCN5A 203+17 b.p.m., P ¼ ns vs. WT, P , 0.05 vs. baseline), but
prevented carbachol-induced arrhythmias in unrestrained DKPQ-
SCN5A mice (TdP or bigemini in 0/11 carbachol challenges, P ,
0.05 vs. in 7/11 in the same mice without ﬂecainide, Figure 3).
4. Discussion
This systematic study of interactions of chronic and acute autonomic
modulation and sodium channel blockade identiﬁed several new ﬁnd-
ings in this model of LQT3:
(1) Cholinergic stimulation provokes bradycardia and arrhythmias
in vivo in this model of LQT3.
(2) Stress and catecholamines suppress arrhythmias in vivo and
shorten ventricular action potentials in this model. INa, late in
DKPQ-SCN5A myocytes is relatively insensitive to b-adrenergic
stimulation.
(3) b-Adrenoceptor-blockade does not prevent arrhythmias, but
blunts the antiarrhythmic effects of catecholamines, and prolongs
repolarization in vivo and in vitro in this model.
(4) Cardiac b-adrenoceptor expression is markedly reduced in this
model of LQT3.
(5) Chronic pharmacological inhibition of sodium currents by
ﬂecainide prevents arrhythmias in vivo in this model of
LQT3.
Within the limitations of a preclinical study, and taken together with
other studies in isolated hearts or in cellular preparations,
12,25–29
our data conﬁrm the clinical observation that patients carrying
sodium channel mutations do not beneﬁt from b-adrenoceptor-
blocker therapy. Cholinergic stimulation appears proarrhythmic in
patients carrying this mutation or SCN5A mutations with similar bio-
physical characteristics. Finally, our data show that chronic sodium
channel inhibition by ﬂecainide can prevent arrhythmias in freely
roaming animals, thereby extending the existing data on sodium
channel blockade in cells and isolated organs.
12,25,26,29
Figure 3 (D) Telemetry heart rate during drug exposures. Alternating heart rate indicates bigemini and arrhythmias. Arrows indicate intraperitoneal
injection of carbachol 0.5 mg/kg BW.
L. Fabritz et al. 664.1 Cholinergic stimulation is highly
arrhythmogenic in this model of LQT3
Cholinergic stimulation had a marked proarrhythmic effect showing





the DKPQ mutant. INa, late is more pronounced at low heart rates in
DKPQ-SCN5A.
29,31–33 These biophysical properties of the mutated
sodium channel can also explain excessive prolongation of QT
interval in response to bradycardia at rest, and a shortening of
repolarization during sinus tachycardia in freely roaming
DKPQ-SCN5A mice in this study. Effects of carbachol on cardiac
electrophysiology are predominantly mediated by muscarinic recep-
tors, most of them of the M2 subtype,
34,35 and muscarinic stimu-
lation does no longer cause bradycardia in M22y2 mutant mice.
36
Carbachol-induced arrhythmias were no longer observed if either
atropine or the muscarinic antagonist AFDX116 was co-applied,
suggesting that muscarinic and preferential M2 activation mediated
the proarrhythmic effect of carbachol in this model.
4.2 Sympathetic stimulation suppresses
and prevents arrhythmias in DKPQ-SCN5A
Endogenous catecholamines shortened QT interval and prevented
arrhythmias in unrestrained DKPQ-SCN5A mice, and even
Figure 4 Carbachol (10
27–10
25 M) provoked marked bradycardia, potential early afterdepolarizations (EADs), and ventricular arrhythmias in iso-
lated, beating DKPQ-SCN5A mouse hearts. (A) Representative monophasic action potential recording of carbachol-induced TdP-like arrhythmias in an
isolated, beating DKPQ-SCN5A mouse heart. Arrows indicate potentially conducted EADs. (B) Representative action potentials during spontaneous
rhythm at baseline and after carbachol perfusion in a DKPQ-SCN5A mouse heart. (C) Mean action potential duration (left) and cycle length (right)
during spontaneous rhythm in DKPQ-SCN5A and WT littermate mouse hearts. Carbachol provoked bradycardia and bradycardia-dependent APD
prolongation in DKPQ-SCN5A mouse hearts (WT n ¼ 24, DKPQ-SCN5A n ¼ 28 hearts; P , 0.05 vs. WT and vs. baseline. Results depicted for car-
bachol 10
26 M; #P , 0.05 for carbachol vs. baseline).
Autonomic modulation and therapy in LQT3 67interrupted arrhythmias induced by cholinergic stimulation in vivo.
b-Adrenoceptor-stimulation completely suppressed TdP in the
intact, beating heart, consistent with reports in transgenic
14,37 and
pharmacological
38 models of LQT3, and reduced the difference of
late sodium current between WTand DKPQ-SCN5A cardiomyocytes.
b-Adrenoceptor-stimulation can affect sodium currents by PKA-
dependent and PKA-independent mechanisms: PKA phosphorylates
cardiac sodium channels, and sodium channels can directly bind to
b-adrenoceptors in conjunction with G-protein a-units.
39 Activation
of a1-adrenoceptors can activate protein kinase C and alter sodium
current.
40,41 a1-Adrenoceptor activation can inhibit sodium channel
bursting via protein kinase C in DKPQ-SCN5A mutant cardiomyo-
cytes.
28,42 Multiple effects have been seen in expression systems,
e.g. in another model of LQT3 using PKA stimulation in transfected
HEK293 cells.
43 The known effects of b-adrenoceptor stimulation
on repolarizing channels may be responsible for catecholamine-
induced action potential shortening in WT and DKPQ-SCN5A
hearts, as their expression is not altered in DKPQ-SCN5A hearts
(RNA of KCNQ1 and KCNE1 encoding IKs, MERG1B encoding IKr,





Chronic b-adrenoceptor-blocker therapy prevented antiarrhythmic
effects of physical stress or catecholamines in freely roaming DKPQ
Figure 5 Antiarrhythmic effect of b-adrenoceptor stimulation in isolated beating hearts. (A) Representative recording of two simultaneous mono-
phasic action potentials (MAP) and ECG during afterdepolarizations and short torsades de pointes (TdP) episodes at baseline after AV block (top left).
TdP are suppressed by b-adrenoceptor stimulation (orciprenaline, top right). Ectopy reappears during co-infusion of orciprenaline and
b-adrenoceptor-blocker esmolol, and pause-triggered TdP occurs during infusion of esmolol alone. (B) Number of DKPQ-SCN5A hearts with
arrhythmias at baseline, with b-adrenoceptor-blockers, during co-infusion of b-adrenoceptor-blockers and orciprenaline, and with orciprenaline
alone; *P , 0.05 vs. baseline (number of hearts depicted as columns).
L. Fabritz et al. 68Figure 6 b-Adrenoceptors and autonomic modulation. (A) Representative monophasic action potential recordings at a pacing cycle length of
200 ms in isolated, beating hearts after mechanical AV block. (B) Mean action potential durations during ﬁxfrequent pacing at baseline, during infusion
of esmolol 1.7   10
26 M, orciprenaline 1.6   10
26 M; and orciprenaline 1.6   10
26 M plus esmolol 1.7   10
26 M. Mean of 19–33 action potentials
from 10 to 11 WT hearts and 11 to 31 action potentials from 10 to 12 DKPQ-SCN5A hearts. At long cycle lengths, number of action potentials was
reduced to ﬁve WT, seven DKPQ-SCN5A, due to fast intrinsic heart rates. (C) b-Adrenoceptor binding was decreased in DKPQ-SCN5A mouse
hearts. Speciﬁc binding of
125I-ICYP to b-adrenoceptors on cryoﬁxated myocardial short axis sections in n ¼ 4–5 per genotype. Binding is expressed
as counts/min/mm
2. Inset shows examples of total ICYP and non-speciﬁc binding in two representative hearts.
Autonomic modulation and therapy in LQT3 69mice and b-adrenoceptor-blocker treatment did not prevent arrhyth-
mias, consistent with observations in LQT3 patients (Table 1 and 2,
Figure 3 and 5
25, Supplementary material online, Figure S3).
4,44–46
b-Adrenoceptor-blockade by esmolol caused lengthening of ventri-
cular action potentials (Figure 6). These observations suggest that
b-adrenoceptor-blockers may not only blunt the beneﬁcial effects of
catecholaminesonventricularactionpotentialdurationandQTinterval
in vivo, but inhibit beneﬁcial effects of ‘endogenous’ catecholamines in
the heart, e.g. stemming from spontaneous release and incomplete
re-uptake of sympathetic granules from sympathetic nerve endings.
4.4 Reduced b-adrenoceptor density
Reduced cardiac b-adrenoceptor density was found in this model
(Figure 6C). Although up to date, little is known about b-adrenoceptor
density in LQT3 patients, reduced b-adrenoceptor density was found
in symptomatic patients with arrhythmogenic right ventricular cardio-
myopathy.
47 As there may be phenotypic variations in patients with
SCN5A mutations (‘overlap syndromes’), our observations warrant
studies of b-adrenoceptor density in LQT3 patients. Reduction of
b-adrenoceptor binding may add another explanation why
b-adrenoceptor-blockers did not prevent ventricular arrhythmias
in DKPQ-SCN5A mice. Reduced b-adrenoceptor expression
in structurally and functionally normal LQT3 hearts invites further
study.
4.5 Antiarrhythmic effects of chronic
ﬂecainide therapy in vivo
Marked b-adrenoceptor-blocker-induced action potential pro-
longation was blunted when propranolol, a b-adrenoceptor-blocker
that is also a weak sodium channel blocker,
48 was used. Long-term
sodium channel blockade by ﬂecainide completely prevented spon-
taneous and carbachol-induced arrhythmias in this study, thereby
extending prior reports of acute effects of sodium channel blockade
in vitro in this model
11,14,15 and in another model of LQT3
49 to ben-
eﬁcial effects of chronic therapy. Our observation of beneﬁcial
effects of chronic sodium channel inhibition in vivo is consistent with
clinical observation.
2 Prevention of arrhythmias by sodium channel
block conﬁrms that abnormal late sodium current is required for
arrhythmias in this LQT3 model in vivo, and supports the notion that
inhibition of late sodium current may be effective in LQT3, in contrast
to b-adrenoceptor-blockade. In addition to sodium current blockade,
ﬂecainide has parasympatholytic effects. This might be considered
as an additional potential antiarrhythmic effect warranting future study.
4.6 Limitations and potential clinical
implications
Afterdepolarizations and triggered beats can be difﬁcult to verify in
MAP even if recording quality is high and standardized. In vivo or
Figure 7 Effect of isoproterenol on sodium current in isolated ventricular cardiomyocytes. (A) Capacity, (B) late current example for WT, (C) peak
current for WT and DKPQ-SCN5A (blue), (D) late current example for DKPQ-SCN5A. (E) refers to peak current and (F) refers to late current. Mean
values shown are derived from seven to 16 cells from nine WT hearts and seven to 18 cells from six DKPQ-SCN5A hearts. Peak sodium current (E)
was unchanged between genotypes. Late sodium current (F) was increased in DKPQ-SCN5A at baseline but no longer different from WT during
b-adrenergic stimulation, *P , 0.05 vs. WT.
L. Fabritz et al. 70in-organ mapping techniques may conﬁrm the role of afterdepolariza-
tions and triggered beats in this model in the future. Our ﬁndings on
sodium currents are in accordance with experiments from Fredj
et al.
12 which showed a difference in late sodium current while
peak currents where not altered. Nuyens et al.
14 reported a higher
peak sodium current in the LQT3 model at high frequencies (10 Hz).
Cholinergic stimulation had arrhythmogenic effects in vivo and in the
isolated heart in DKPQ-SCN5A, suggesting that parasympatholytic
agents such as atropine may be antiarrhythmic in LQT3. Comparable
to the ﬁndings reported here, sinus bradycardia, spontaneous pauses,
and atrioventricular block (see Supplementary material online,
Figure S3) were observed in patients with LQTS3.
4,50 Bradycardia in
LQT3 may be due to altered inactivation kinetics in the sinus
node,
51 and/or to electrotonic modulation of sinus nodal ﬁring by
surrounding cells. This warrants further study.
Electrical storm in patients with Brugada syndrome has been suc-
cessfully treated with b-mimetic agents (e.g. isoproterenol) or quini-
dine, whereas parasympathetic stimulation and b-adrenoceptor-
blockade may provoke arrhythmias in Brugada syndrome. It is concei-
vable that some of the pathophysiological mechanisms observed here
may also apply to selected patients with a Brugada ECG pattern,
sodium channel mutation, and ‘overlap syndromes’ although biophysi-
cal properties of SCN5A mutations found in Brugada syndrome
usually cause loss-of-function.
Chronic sodium channel blockade suppressed spontaneous and
carbachol-induced arrhythmias in vivo and in the beating heart in this
model of LQT3. Our ﬁndings may apply to other forms of LQT3.
50
Within the limitations of a preclinical study, our data provide
another rationale for genetic testing and clinical alertness
5 in LQT
patients to identify those with sodium channel mutations, in order
to start or maintain sodium channel blocker therapy.
13,52 Conduction
slowing and aggravation of bradycardia by sodium channel blocking
drugs must be considered.
53–55 More selective inhibitors of the
INa, late like mexiletine or ranolazine may be considered in LQT3
patients at risk of arrhythmias due to conduction slowing.
These preclinical ﬁndings cannot be directly transferred to clinical
situations noting differences between mice and men. Nonetheless,
reduced b-adrenoceptor density, prolongation of ventricular action
potentials by esmolol, and lack of antiarrhythmic effects of
b-adrenoceptor-blockers in vivo caution use of b-adrenoceptor-
blockers in LQT3, especially when published reports in this model
are considered, and suggest that catecholamines may have acute anti-
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